Compare Dishman Pharma with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NEULAND LABS - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NEULAND LABS DISHMAN PHARMA/
NEULAND LABS
 
P/E (TTM) x 25.1 53.9 46.6% View Chart
P/BV x 3.3 4.1 82.1% View Chart
Dividend Yield % 0.7 0.1 749.3%  

Financials

 DISHMAN PHARMA   NEULAND LABS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NEULAND LABS
Mar-20
DISHMAN PHARMA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs374754 49.7%   
Low Rs129247 52.1%   
Sales per share (Unadj.) Rs197.8594.5 33.3%  
Earnings per share (Unadj.) Rs21.212.6 167.9%  
Cash flow per share (Unadj.) Rs34.737.0 93.8%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.4 198.9%  
Book value per share (Unadj.) Rs179.9553.4 32.5%  
Shares outstanding (eoy) m80.6912.83 628.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.8 151.1%   
Avg P/E ratio x11.939.6 30.0%  
P/CF ratio (eoy) x7.213.5 53.6%  
Price / Book Value ratio x1.40.9 154.7%  
Dividend payout %9.415.8 59.6%   
Avg Mkt Cap Rs m20,3066,421 316.2%   
No. of employees `0000.81.3 64.7%   
Total wages/salary Rs m5,3551,236 433.4%   
Avg. sales/employee Rs Th19,252.75,949.4 323.6%   
Avg. wages/employee Rs Th6,459.5963.8 670.2%   
Avg. net profit/employee Rs Th2,064.1126.4 1,632.6%   
INCOME DATA
Net Sales Rs m15,9617,627 209.3%  
Other income Rs m26539 683.1%   
Total revenues Rs m16,2267,666 211.7%   
Gross profit Rs m4,1031,019 402.7%  
Depreciation Rs m1,091313 348.7%   
Interest Rs m944216 437.8%   
Profit before tax Rs m2,334529 441.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624367 169.9%   
Profit after tax Rs m1,711162 1,055.7%  
Gross profit margin %25.713.4 192.4%  
Effective tax rate %26.769.4 38.5%   
Net profit margin %10.72.1 504.5%  
BALANCE SHEET DATA
Current assets Rs m11,0185,152 213.9%   
Current liabilities Rs m9,5173,576 266.1%   
Net working cap to sales %9.420.7 45.5%  
Current ratio x1.21.4 80.4%  
Inventory Days Days110105 105.2%  
Debtors Days Days3591 38.3%  
Net fixed assets Rs m16,3043,969 410.8%   
Share capital Rs m161129 125.1%   
"Free" reserves Rs m12,9076,971 185.2%   
Net worth Rs m14,5167,100 204.5%   
Long term debt Rs m4,189774 541.5%   
Total assets Rs m29,80512,310 242.1%  
Interest coverage x3.53.5 100.5%   
Debt to equity ratio x0.30.1 264.8%  
Sales to assets ratio x0.50.6 86.4%   
Return on assets %8.93.1 290.3%  
Return on equity %11.82.3 516.4%  
Return on capital %17.59.5 185.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9525,187 95.5%   
Fx outflow Rs m6971,593 43.7%   
Net fx Rs m4,2553,594 118.4%   
CASH FLOW
From Operations Rs m2,786573 485.9%  
From Investments Rs m-1,529-487 314.1%  
From Financial Activity Rs m-941-55 1,717.3%  
Net Cashflow Rs m31633 970.6%  

Share Holding

Indian Promoters % 61.4 36.3 169.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 63.7 5.8%  
FIIs % 12.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 63.7 34.7%  
Shareholders   46,261 12,705 364.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  FDC  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS